Fifty-two JIA
patients with AR were enrolled and consecutively randomized. The control group
comprised 26 patients who were treated with methotrexate (MTX) 10-15 mg/m2/week
orally for 12 months and enteric-coated diclofenac
sodium 0.5-2 mg/kg/day orally for 12 weeks.
The test group
comprised 26 patients who received adjunctive therapy with oral and intranasal
antihistamines for 12 months, in addition to MTX and diclofenac.
The responses
were evaluated using American College of Rheumatology (ACR) pediatric (Pedi)
30/50/70 criteria, AR score, 27-joint Juvenile Arthritis Disease Activity Score
(JADAS-27), and laboratory variables.
No comments:
Post a Comment